Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Table 9 Survival in trials comparing gemcitabine to gemcitabine plus other cytotoxic agent

Reference	Year	Treatment regimen	Median survival (mo)	P	HR	95% CI
Oettle	2005	Gemcitabine	6.3	0.848	0.98	0.82 – 1.18
		Gemcitabine + Pemetrexed	6.2
Rocha Lima	2004	Gemcitabine	6.6	0.789	1.04	0.84 – 1.30
		Gemcitabine + Irinotecan	6.3
Stathopoulos	2006	Gemcitabine	6.5	0.970	na	na
		Gemcitabine + Irinotecan	6.4
O'Reilly	2004	Gemcitabine	6.2	0.52	0.93	0.74 – 1.17
		Gemcitabine + Exatecan	6.7

ISSN: 1471-2407